CYP2D6 allelic frequencies in young-onset Parkinson's disease

被引:41
作者
Sandy, MS
Armstrong, M
Tanner, CM
Daly, AK
DiMonte, DA
Langston, JW
Idle, JR
机构
[1] PARKINSONS INST,SUNNYVALE,CA
[2] UNIV NEWCASTLE UPON TYNE,SCH MED,DEPT PHARMACOL SCI,PHARMACOGENET RES UNIT,NEWCASTLE TYNE NE1 7RU,TYNE & WEAR,ENGLAND
关键词
D O I
10.1212/WNL.47.1.225
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Parkinson's disease (PD) is thought to develop as a result of interactions between genetic susceptibility factors and environmental exposures. One candidate gene is CYP2D6, which codes for the debrisoquine 4-hydroxylase cytochrome P450. Impairment of debrisoquine 4-hydroxylase activity has been associated with an increased risk of PD in patients with younger age at disease onset. Genotyping studies in patients with an older age at onset have reported modest increases in risk associated with the CYP2D6 B and A alleles; however, the risk for young-onset PD has not been adequately evaluated. We designed a case-control study to investigate the role of nonfunctional CYP2D6 allelic risk factors for young-onset PD in a sizable patient population and compared the distributions of CYP2D6 genotypes between young-onset (less than or equal to 51 years) PD patients (n = 108) and controls (n = 236). In contrast with the results from genotyping studies conducted among patients with an older age at onset, there were no significant differences in CYP2D6 allelic frequencies between young-onset PD cases and controls. The frequency of the B allele was slightly lower in the young-onset PD cases than in the controls (0.14 versus 0.20) (chi(2) = 2.66, p = 0.10). The presence of one or more B alleles was not associated with an increased risk of young-onset PD (odds ratio 0.58; 95% CI 0.33 to 1.00), nor was the presence of one or more nonfunctional alleles (i.e., A, B, D, and D2) (odds ratio 0.68; 95% CI 0.41 to 1.13). This study suggests that the young-onset PD population may differ from the older-onset population with respect to risk factors.
引用
收藏
页码:225 / 230
页数:6
相关论文
共 51 条
[1]   ASSOCIATION BETWEEN THE OXIDATIVE POLYMORPHISM AND EARLY-ONSET OF PARKINSONS-DISEASE [J].
AGUNDEZ, JAG ;
JIMENEZJIMENEZ, FJ ;
LUENGO, A ;
BERNAL, ML ;
MOLINA, JA ;
AYUSO, L ;
VAZQUEZ, A ;
PARRA, J ;
DUARTE, J ;
CORIA, F ;
LADERO, JM ;
ALVAREZ, JC ;
BENITEZ, J .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1995, 57 (03) :291-298
[2]   HYDROXYLATION POLYMORPHISMS OF DEBRISOQUINE AND MEPHENYTOIN IN EUROPEAN POPULATIONS [J].
ALVAN, G ;
BECHTEL, P ;
ISELIUS, L ;
GUNDERTREMY, U .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 39 (06) :533-537
[3]  
ARMSTRONG M, 1993, HUM GENET, V91, P616
[4]   MUTANT DEBRISOQUINE HYDROXYLATION GENES IN PARKINSONS-DISEASE [J].
ARMSTRONG, M ;
DALY, AK ;
CHOLERTON, S ;
BATEMAN, DN ;
IDLE, JR .
LANCET, 1992, 339 (8800) :1017-1018
[5]   ETIOLOGY OF PARKINSONS-DISEASE - A RESEARCH STRATEGY [J].
BARBEAU, A .
CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES, 1984, 11 (01) :24-28
[6]   SMOKING, CANCER, AND PARKINSONS-DISEASE [J].
BARBEAU, A ;
ROY, M ;
CLOUTIER, T .
ANNALS OF NEUROLOGY, 1986, 20 (01) :105-106
[7]  
BARBEAU A, 1985, LANCET, V2, P1213
[8]   OXIDATIVE POLYMORPHISM OF DEBRISOQUINE IN PARKINSONS-DISEASE [J].
BENITEZ, J ;
LADERO, JM ;
JIMENEZJIMENEZ, FJ ;
MARTINEZ, C ;
PUERTO, AM ;
VALDIVIELSO, MJ ;
LLERENA, A ;
COBALEDA, J ;
MUNOZ, JJ .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1990, 53 (04) :289-292
[9]   GENERAL METHOD FOR ISOLATION OF HIGH MOLECULAR-WEIGHT DNA FROM EUKARYOTES [J].
BLIN, N ;
STAFFORD, DW .
NUCLEIC ACIDS RESEARCH, 1976, 3 (09) :2303-2308
[10]   LUNG-CANCER AND THE DEBRISOQUINE METABOLIC PHENOTYPE [J].
CAPORASO, NE ;
TUCKER, MA ;
HOOVER, RN ;
HAYES, RB ;
PICKLE, LW ;
ISSAQ, HJ ;
MUSCHIK, GM ;
GREENGALLO, L ;
BUIVYS, D ;
AISNER, S ;
RESAU, JH ;
TRUMP, BF ;
TOLLERUD, D ;
WESTON, A ;
HARRIS, CC .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1990, 82 (15) :1264-1272